Serum calcium is an independent predictor of quality of life in multiple myeloma

European Journal of Haematology

Volumn 78, Issue 1, 2007, Pages 29-34

  Wisløff, Finn ^a   Kvam, Ann Kristin ^a   Hjorth, Martin ^b   Lenhoff, Stig ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Department of Pediatrics   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Disease parameters; Hypercalcaemia; Multiple regression; Myeloma; Quality of life; Serum calcium

Indexed keywords

CALCIUM; HEMOGLOBIN;

ADULT; AGED; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CANCER PATIENT; COGNITION; DATA ANALYSIS; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA AND VOMITING; PAIN; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

EID: 33845878815     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.0902-4441.2006.t01-1-EJH2887.x     Document Type: Article

References (17)

1. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758-69.
2. Greer JP. Wintrobe's Clinical Hematology. Philadelphia, PA: Lippincott Williams & Wilkins, 2004.
3. Chan AK, Duh Q-Y, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. Ann Surg 1995;222:402-14.
4. Burney RE, Jones KR, Coon JW, Blewitt DK, Herm AM. Assessment of patient outcomes after operation for primary hyperparathyroidism. Surgery 1995;120:1013-9.
5. Gulbrandsen N, Hjermstad MJ, Wisloff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004;72:172-80.
6. Hjorth M, Westin J, Dahl IM, et al. Interferon-alpha2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Int Med 1996;124:212-22.
7. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996;94:324-32.
8. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
9. Gulbrandsen N, Wisloff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65-77.
10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993;85:365-76.
11. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Bottomley A. The EORTC QLQ-C30 Scoring Manual, 3rd edn. Brussels: European Organization for Research and Treatment of Cancer, 2002.
12. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Using reference data on quality of life - the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 1998;34:1381-9.
13. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, and Quality of Life Committee of the NCIC CTG. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-7.
14. Hasse C, Sitter H, Brune M, Wollenteit I, Nies C, Rothmund M. Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results. World J Surg 2002;26:1029-36.
15. Wisloff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol 2005;75:293-8.
16. Iwase M, Takemi T, Manabe M, Nagumo M. Hypercalcemic complication in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2003;32:174-80.
17. Lamy O, Jenzer-Closuit A, Burckhardt P. Hypercalcaemia of malignancy: an undiagnosed and undertreated disease. J Int Med 2001;250:73-9.